Literature DB >> 11773394

Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines.

Sabine Wellnitz1, Bettina Klumpp, Heidi Barth, Susumu Ito, Erik Depla, Jean Dubuisson, Hubert E Blum, Thomas F Baumert.   

Abstract

Hepatitis C virus (HCV) is a leading cause of chronic hepatitis in the world. The study of viral entry and infection has been hampered by the inability to efficiently propagate the virus in cultured cells and the lack of a small-animal model. Recent studies have shown that in insect cells, the HCV structural proteins assemble into HCV-like particles (HCV-LPs) with morphological, biophysical, and antigenic properties similar to those of putative virions isolated from HCV-infected humans. In this study, we used HCV-LPs derived from infectious clone H77C as a tool to examine virus-cell interactions. The binding of partially purified particles to human cell lines was analyzed by fluorescence-activated cell sorting with defined monoclonal antibodies to envelope glycoprotein E2. HCV-LPs demonstrated dose-dependent and saturable binding to defined human lymphoma and hepatoma cell lines but not to mouse cell lines. Binding could be inhibited by monoclonal anti-E2 antibodies, indicating that the HCV-LP-cell interaction was mediated by envelope glycoprotein E2. Binding appeared to be CD81 independent and did not correlate with low-density lipoprotein receptor expression. Heat denaturation of HCV-LPs drastically reduced binding, indicating that the interaction of HCV-LPs with target cells was dependent on the proper conformation of the particles. In conclusion, our data demonstrate that insect cell-derived HCV-LPs bind specifically to defined human cell lines. Since the envelope proteins of HCV-LPs are presumably presented in a virion-like conformation, the binding of HCV-LPs to target cells may allow the study of virus-host cell interactions, including the isolation of HCV receptor candidates and antibody-mediated neutralization of binding.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11773394      PMCID: PMC135804          DOI: 10.1128/jvi.76.3.1181-1193.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor.

Authors:  S Wünschmann; J D Medh; D Klinzmann; W N Schmidt; J T Stapleton
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Interaction of recombinant norwalk virus particles with the 105-kilodalton cellular binding protein, a candidate receptor molecule for virus attachment.

Authors:  M Tamura; K Natori; M Kobayashi; T Miyamura; N Takeda
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Human papillomavirus infection requires cell surface heparan sulfate.

Authors:  T Giroglou; L Florin; F Schäfer; R E Streeck; M Sapp
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

4.  Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells.

Authors:  A Wack; E Soldaini; C Tseng; S Nuti; G Klimpel; S Abrignani
Journal:  Eur J Immunol       Date:  2001-01       Impact factor: 5.532

5.  Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm.

Authors:  Y Kawana; K Kawana; H Yoshikawa; Y Taketani; K Yoshiike; T Kanda
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

6.  Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice.

Authors:  M Lechmann; K Murata; J Satoi; J Vergalla; T F Baumert; T J Liang
Journal:  Hepatology       Date:  2001-08       Impact factor: 17.425

7.  Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens.

Authors:  O Vidalin; A Fournillier; N Renard; M Chen; E Depla; D Boucreux; C Brinster; T Baumert; I Nakano; Y Fukuda; P Liljeström; C Trépo; G Inchauspé
Journal:  Virology       Date:  2000-10-25       Impact factor: 3.616

8.  Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies.

Authors:  M D Yeager; M Aste-Amezaga; D R Brown; M M Martin; M J Shah; J C Cook; N D Christensen; C Ackerson; R S Lowe; J F Smith; P Keller; K U Jansen
Journal:  Virology       Date:  2000-12-20       Impact factor: 3.616

9.  Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding.

Authors:  Arvind H Patel; Jonny Wood; Francois Penin; Jean Dubuisson; J A McKeating
Journal:  J Gen Virol       Date:  2000-12       Impact factor: 3.891

10.  Efficient initiation of HCV RNA replication in cell culture.

Authors:  K J Blight; A A Kolykhalov; C M Rice
Journal:  Science       Date:  2000-12-08       Impact factor: 47.728

View more
  34 in total

1.  Identification of the hepatitis C virus E2 glycoprotein binding site on the large extracellular loop of CD81.

Authors:  Heidi E Drummer; Kirilee A Wilson; Pantelis Poumbourios
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

Review 2.  Studying hepatitis C virus: making the best of a bad virus.

Authors:  Timothy L Tellinghuisen; Matthew J Evans; Thomas von Hahn; Shihyun You; Charles M Rice
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

Review 3.  New therapeutic opportunities for hepatitis C based on small RNA.

Authors:  Qiu-Wei Pan; Scot D Henry; Bob J Scholte; Hugo W Tilanus; Harry L A Janssen; Luc J W van der Laan
Journal:  World J Gastroenterol       Date:  2007-09-07       Impact factor: 5.742

4.  HCV entry and neutralizing antibodies: lessons from viral variants.

Authors:  Mirjam B Zeisel; Thomas F Baumert
Journal:  Future Microbiol       Date:  2009-06       Impact factor: 3.165

Review 5.  Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design.

Authors:  Leopold Kong; Kelli N Jackson; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2015-04-29       Impact factor: 7.090

6.  Replication of subgenomic hepatitis C virus replicons in mouse fibroblasts is facilitated by deletion of interferon regulatory factor 3 and expression of liver-specific microRNA 122.

Authors:  Liang-Tzung Lin; Ryan S Noyce; Tram N Q Pham; Joyce A Wilson; Gary R Sisson; Thomas I Michalak; Karen L Mossman; Christopher D Richardson
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

7.  Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen.

Authors:  Leopold Kong; David E Lee; Rameshwar U Kadam; Tong Liu; Erick Giang; Travis Nieusma; Fernando Garces; Netanel Tzarum; Virgil L Woods; Andrew B Ward; Sheng Li; Ian A Wilson; Mansun Law
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-24       Impact factor: 11.205

8.  Hepatitis C virus targets DC-SIGN and L-SIGN to escape lysosomal degradation.

Authors:  Irene S Ludwig; Annemarie N Lekkerkerker; Erik Depla; Fons Bosman; René J P Musters; Stany Depraetere; Yvette van Kooyk; Teunis B H Geijtenbeek
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

Review 9.  Neutralizing antibodies in hepatitis C virus infection.

Authors:  Mirjam-B Zeisel; Samira Fafi-Kremer; Isabel Fofana; Heidi Barth; Francoise Stoll-Keller; Michel Doffoel; Thomas-F Baumert
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

10.  CD81 is required for hepatitis C virus glycoprotein-mediated viral infection.

Authors:  Jie Zhang; Glenn Randall; Adrian Higginbottom; Peter Monk; Charles M Rice; Jane A McKeating
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.